Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

While ER-positive/HER2-positive breast cancer typically yields lower pCR rates (34% overall), the HER2-DX pCR score revealed an absolute 40% difference between low and high/medium scores. Patients with ER-positive tumors and high or medium scores achieved pCR rates of 58% to 61% with four cycles of THP, effectively identifying candidates who can safely forgo multi-agent chemotherapy despite traditionally lower response expectations.

Related Insights

For lower-risk Stage 2/3 HER2+ breast cancer, clinicians can start with THP, assess response via MRI, and only then proceed to TDXD if necessary. This risk-stratified approach to the DESTINY-Breast11 regimen can spare some patients the unique toxicities of TDXD.

Expert clinicians select genomic assays with nuance. For a patient where a low-risk result is desired to avoid chemotherapy, Oncotype DX may be chosen as it tends to yield more low-risk scores. Conversely, MammaPrint may be used for a chemo-hesitant patient, as it is more likely to return a high-risk result.

Trials like TaylorX and MINDACT use genomic scores to identify patients with early-stage, HR+/HER2- breast cancer who won't benefit from adjuvant chemotherapy. This avoids significant toxicity for two-thirds to over 80% of patients who would have received it under older guidelines, without compromising their outcomes.

Hormone receptor-positive (HR+) HER2+ breast cancers often show lower rates of pathologic complete response (pCR) to pre-surgical therapy. This is due to their slower-growing biology, not treatment ineffectiveness. Clinicians should recognize this nuance and not assume a worse prognosis based on pCR alone in this subtype.

Data from the Optima trial shows the ProSigna (PAM50) gene signature can identify premenopausal ER+ breast cancer patients, even those with high nodal burden, who can safely forgo chemotherapy. For those with a low-risk score, adequate ovarian suppression alone provides sufficient benefit, marking a major step in treatment de-escalation.

The DESTINY-Breast11 trial showed a neoadjuvant regimen of TDXD followed by THP achieved a 67.3% pathologic complete response (pCR) rate in high-risk HER2+ breast cancer. This is the highest pCR rate seen in a registrational trial, signaling a potential new standard of care.

For patients with 1-3 positive nodes and low-risk biology (e.g., low-grade lobular, low recurrence score), experts are comfortable deferring chemotherapy. This challenges traditional node-based risk assessment, prioritizing tumor biology to avoid unnecessary toxicity in otherwise high-risk patients.

In HR+/HER2- early breast cancer, registry data shows only the MammaPrint High-2 (ultra-high risk) subgroup derives significant benefit from adding anthracycline-based chemotherapy. This NCCN-adopted finding allows for therapy de-escalation in MammaPrint High-1 patients, sparing them unnecessary toxicity.

In the CompassHER2 analysis, anatomical factors like nodal involvement and T stage did not predict pathologic complete response, with the lone exception of T3 tumors in ER-negative disease. Dr. Nadine Tung highlights that biological factors—such as receptor expression and genomic signatures—drive chemosensitivity much more than anatomical tumor volume, suggesting clinicians should base de-escalation decisions primarily on biological characteristics.

HER2+/ER+ breast cancer is not a single disease. Genomic subtyping reveals distinct biological profiles (luminal A/B, HER2-enriched) with pathologic complete response rates to therapy ranging from just 26% to as high as 61%, signaling the need for tailored treatment strategies.